[go: up one dir, main page]

AR087567A1 - Anticuerpos anti-tie2 y usos de los mismos - Google Patents

Anticuerpos anti-tie2 y usos de los mismos

Info

Publication number
AR087567A1
AR087567A1 ARP120103012A ARP120103012A AR087567A1 AR 087567 A1 AR087567 A1 AR 087567A1 AR P120103012 A ARP120103012 A AR P120103012A AR P120103012 A ARP120103012 A AR P120103012A AR 087567 A1 AR087567 A1 AR 087567A1
Authority
AR
Argentina
Prior art keywords
tie2
binding fragment
antibody
amino acids
antigen
Prior art date
Application number
ARP120103012A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR087567A1 publication Critical patent/AR087567A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Reivindicación 1: Un anticuerpo aislado o fragmento de unión al antígeno del mismo que se une de manera específica a Tie2 humano y bloquea la interacción entre Tie2 y un ligando de Tie2. Reivindicación 5: El anticuerpo o fragmento de unión al antígeno de cualquiera de las reivindicaciones 1 a 4, en el que el anticuerpo o fragmento de unión al antígeno interacciona con uno o más aminoácidos localizados en uno o más segmentos de aminoácidos seleccionados del grupo que consiste en los aminoácidos 96 - 106 de SEQ ID Nº 7, aminoácidos 139 - 152 de SEQ ID Nº 7; y aminoácidos 166 - 175 de SEQ ID Nº 7. Reivindicación 13: Una composición farmacéutica que comprende el anticuerpo o el fragmento de unión al antígeno de cualquiera de las reivindicaciones 1 a 12, y un vehículo o diluyente farmacéuticamente aceptable. Reivindicación 20: Un método para inhibir el crecimiento de un tumor en un paciente, y el método comprende administrar al paciente una composición farmacéutica que comprende un anticuerpo o fragmento de unión al antígeno del mismo que se une de manera específica a Tie2 humano y bloquea la interacción entre Tie2 y un ligando de Tie2.
ARP120103012A 2011-08-19 2012-08-16 Anticuerpos anti-tie2 y usos de los mismos AR087567A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525308P 2011-08-19 2011-08-19
US201261587213P 2012-01-17 2012-01-17
US201261674405P 2012-07-23 2012-07-23

Publications (1)

Publication Number Publication Date
AR087567A1 true AR087567A1 (es) 2014-04-03

Family

ID=46785799

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103012A AR087567A1 (es) 2011-08-19 2012-08-16 Anticuerpos anti-tie2 y usos de los mismos

Country Status (15)

Country Link
US (4) US9017670B2 (es)
EP (2) EP3415533A1 (es)
JP (2) JP6333174B2 (es)
KR (1) KR20140054303A (es)
CN (2) CN106963946A (es)
AR (1) AR087567A1 (es)
AU (1) AU2012299195B9 (es)
CA (1) CA2844306C (es)
ES (1) ES2694411T3 (es)
IL (1) IL230529A (es)
IN (1) IN2014CN02025A (es)
MX (1) MX359833B (es)
SG (1) SG10201606872TA (es)
UY (1) UY34271A (es)
WO (1) WO2013028442A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6333174B2 (ja) 2011-08-19 2018-05-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｔｉｅ２抗体およびその使用
US10316105B2 (en) 2011-08-19 2019-06-11 Regeneron Pharmaceuticals, Inc. Anti-TIE2 antibodies and uses thereof
LT3062811T (lt) 2013-11-01 2019-05-10 Regeneron Pharmaceuticals, Inc. Intervencijos angiopoietino pagrindu cerebrinės maliarijos gydymui
MA40182A (fr) 2014-07-15 2017-05-24 Astellas Pharma Inc NOUVEL ANTICORPS ANTI-Tie2 HUMAIN
WO2016115092A1 (en) * 2015-01-12 2016-07-21 La Jolla Institute For Allergy And Immunology Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
EP3580568A1 (en) 2017-02-09 2019-12-18 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting immunotherapy intervention
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
CN112399975B (zh) * 2018-06-07 2024-05-17 基础科学研究院 与Tie2结合的抗体及其用途
WO2019235856A1 (ko) * 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
US11001635B2 (en) 2018-06-29 2021-05-11 Gensun Biopharma Inc. Antitumor antagonists
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
MX2021012869A (es) * 2019-08-14 2021-12-10 Pharmabcine Inc Anticuerpo anti-tie2 y uso del mismo.
AU2020385991A1 (en) * 2019-11-21 2022-06-23 Unity Biotechnology Antibodies directed to Tie-2 and methods of use
PE20230414A1 (es) 2020-03-24 2023-03-07 Genentech Inc Agentes de fijacion a tie2 y metodos de uso
WO2022225182A1 (ko) * 2021-04-23 2022-10-27 (주)니오테스바이오 안지오포이에틴-2에 특이적으로 결합하는 항체, 또는 이의 단편
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
CA3242904A1 (en) * 2022-01-13 2025-03-14 Ingenia Therapeutics Inc. VEGF-BINDING AND TIE2 FUSION PROTEIN AND ITS USES
CN115947818B (zh) * 2022-10-25 2024-08-02 福州大学 一种血管生成素1突变体的设计及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994000469A1 (en) 1992-06-26 1994-01-06 Immunex Corporation Novel tyrosine kinase
US5681714A (en) 1992-07-30 1997-10-28 Mount Sinai Hospital Corporation Nucleic acid encoding tek receptor tyrosine kinase
AU8143094A (en) 1993-11-12 1995-05-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. (tie-2), a novel receptor tyrosine kinase
AUPM379494A0 (en) 1994-02-10 1994-03-03 Ludwig Institute For Cancer Research Immunointeractive molecules - ii
US20030040463A1 (en) * 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
US6365154B1 (en) 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies
WO2000075323A1 (en) 1999-06-07 2000-12-14 Immunex Corporation Tek antagonists
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP2298333A3 (en) * 1999-12-20 2012-05-02 Immunex Corporation Tweak receptor
HRP20030041A2 (en) 2000-06-23 2005-02-28 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor fuction and their use (ii)
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
WO2006005361A1 (en) * 2004-07-13 2006-01-19 Centre National De La Recherche Scientifique Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses
CA2576886A1 (en) * 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
WO2006112479A1 (ja) 2005-04-19 2006-10-26 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
PT2076290T (pt) 2006-10-27 2017-01-17 Sunnybrook Health Sciences Center Agonistas de tie 2 multiméricos e utilizações dos mesmos na estimulação da angiogénese
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US8685393B2 (en) 2008-03-24 2014-04-01 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of systemic anthrax infection
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20130188013A1 (en) * 2011-07-22 2013-07-25 Qualcomm Incorporated Mvc based 3dvc codec supporting inside view motion prediction (ivmp) mode
JP6333174B2 (ja) 2011-08-19 2018-05-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｔｉｅ２抗体およびその使用

Also Published As

Publication number Publication date
US20170088622A1 (en) 2017-03-30
CN106963946A (zh) 2017-07-21
JP2017186347A (ja) 2017-10-12
JP6654165B2 (ja) 2020-02-26
US9017670B2 (en) 2015-04-28
KR20140054303A (ko) 2014-05-08
US20130209492A1 (en) 2013-08-15
US20150197578A1 (en) 2015-07-16
US20180291105A1 (en) 2018-10-11
WO2013028442A1 (en) 2013-02-28
AU2012299195A1 (en) 2014-03-13
EP2744827A1 (en) 2014-06-25
JP2014525934A (ja) 2014-10-02
US10023641B2 (en) 2018-07-17
CN103874709A (zh) 2014-06-18
US10442864B2 (en) 2019-10-15
NZ621481A (en) 2016-04-29
SG10201606872TA (en) 2016-10-28
MX2014001738A (es) 2014-03-27
ES2694411T3 (es) 2018-12-20
CA2844306C (en) 2022-08-16
CN103874709B (zh) 2016-12-21
JP6333174B2 (ja) 2018-05-30
CA2844306A1 (en) 2013-02-28
IL230529A0 (en) 2014-03-31
UY34271A (es) 2013-02-28
US9546218B2 (en) 2017-01-17
EP2744827B1 (en) 2018-10-03
AU2012299195B2 (en) 2018-04-19
EP3415533A1 (en) 2018-12-19
IN2014CN02025A (es) 2015-05-29
AU2012299195B9 (en) 2018-05-10
IL230529A (en) 2017-07-31
MX359833B (es) 2018-10-12

Similar Documents

Publication Publication Date Title
AR087567A1 (es) Anticuerpos anti-tie2 y usos de los mismos
AR122771A2 (es) Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
AR124676A2 (es) Formulación farmacéutica que comprende una droga biofarmacéutica
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
AR094141A1 (es) Composiciones y metodos para proteinas de accion prolongada
AR105654A1 (es) Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
AR085955A1 (es) Proteinas de union al antigeno
PE20141271A1 (es) Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
AR086360A1 (es) Polipeptidos anticuerpos que antagonizan cd40
AR085281A1 (es) Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
AR110101A1 (es) Miembros de unión (2)
AR095432A1 (es) Proteínas de unión a antígeno
PE20142167A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
RU2013148537A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
MX363642B (es) Metodos para reducir los niveles de lipoproteina (a) administrando un inhibidor de proproteina convertasa subtilisina kexina-9 (pcsk9).
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
AR083747A1 (es) Anticuerpos anti-il-23
UA113728C2 (xx) Фармацевтична композиція, яка містить антитіло до pcsk9 людини

Legal Events

Date Code Title Description
FB Suspension of granting procedure